Literature DB >> 20826058

Does transthyretin function as one of contributors for preeclampsia?

Yuxuan Chen1, Zhenyu Zhang.   

Abstract

Preeclampsia (PE) is a multi-system disorder of pregnancy, which is characterized by new onset hypertension and proteinuria, resulting in multi-organ damages within a potential procedure. However as a worldwide leading cause of maternal and fetal mortality and morbidity, the precise origin of PE has not been clarified yet, which also makes obstacles to the management of the disease. Transthyretin (TTR) is a special protein involved in amyloid diseases, has important effects on amyloid fibrils formation. We assumed that TTR might cause a disorder of maternal vascular function and contributed to the pathology of the disease by deposition of TTR amyloid fibrils in the vascular system, which are produced by variant TTR proteins, resulting in organ ischemia. If this hypothesis proves to be correct, this variant may be of diagnostic importance as novel biomarkers for the disease, in addition, it might also benefit to the management of PE. Crown
Copyright © 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826058      PMCID: PMC4497516          DOI: 10.1016/j.mehy.2010.08.017

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  28 in total

1.  Oxidized transthyretin in amniotic fluid as an early marker of preeclampsia.

Authors:  Carlo Vascotto; Anna Maria Salzano; Chiara D'Ambrosio; Arrigo Fruscalzo; Diego Marchesoni; Carla di Loreto; Andrea Scaloni; Gianluca Tell; Franco Quadrifoglio
Journal:  J Proteome Res       Date:  2007-01       Impact factor: 4.466

Review 2.  Prediction tests for recurrent hypertensive disease in pregnancy, a systematic review.

Authors:  Simone Sep; Luc Smits; Martin Prins; Louis Peeters
Journal:  Hypertens Pregnancy       Date:  2010-01       Impact factor: 2.108

3.  Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease.

Authors:  R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Biochemistry       Date:  2005-12-20       Impact factor: 3.162

4.  TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?

Authors:  Bernard Bonaïti; Malin Olsson; Urban Hellman; Ole Suhr; Catherine Bonaïti-Pellié; Violaine Planté-Bordeneuve
Journal:  Eur J Hum Genet       Date:  2010-03-17       Impact factor: 4.246

Review 5.  Amyloid in the cardiovascular system: a review.

Authors:  I Kholová; H W M Niessen
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

6.  Birth of two healthy females after preimplantation genetic diagnosis for familial amyloid polyneuropathy.

Authors:  V M Almeida; P M Costa; P Moreira; J Gonçalves; J Braga
Journal:  Reprod Biomed Online       Date:  2005-05       Impact factor: 3.828

7.  Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.

Authors:  Francesca Lavatelli; David H Perlman; Brian Spencer; Tatiana Prokaeva; Mark E McComb; Roger Théberge; Lawreen H Connors; Vittorio Bellotti; David C Seldin; Giampaolo Merlini; Martha Skinner; Catherine E Costello
Journal:  Mol Cell Proteomics       Date:  2008-05-12       Impact factor: 5.911

Review 8.  Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections.

Authors:  Jeffrey S Gilbert; Mark J Nijland; Penny Knoblich
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-11

9.  Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

10.  Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture.

Authors:  Natàlia Reixach; Songpon Deechongkit; Xin Jiang; Jeffery W Kelly; Joel N Buxbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

View more
  5 in total

1.  Human placental transthyretin in fetal growth restriction in combination with preeclampsia and the HELLP syndrome.

Authors:  Arrigo Fruscalzo; R Schmitz; W Klockenbusch; G Köhler; A P Londero; M Siwetz; B Huppertz
Journal:  Histochem Cell Biol       Date:  2012-07-31       Impact factor: 4.304

2.  Transthyretin regulates the migration and invasion of JEG-3 cells.

Authors:  Liyun Gong; Lei Zhu; Shuzhen Wang; Zhenyu Zhang
Journal:  Oncol Lett       Date:  2016-12-28       Impact factor: 2.967

3.  Serum Protein Profile in Women With Pregnancy Morbidity Associated With Antiphospholipid Syndrome.

Authors:  Angela M Alvarez; Stefan Neubeck; Sergio Parra; Udo R Markert; Angela P Cadavid
Journal:  J Hum Reprod Sci       Date:  2017 Jan-Mar

4.  Transthyretin as a novel candidate biomarker for preeclampsia.

Authors:  Lei Zhu; Yuxuan Chen; Chongdong Liu; Haiteng Deng; Nawei Zhang; Shengdian Wang; Zhenyu Zhang
Journal:  Exp Ther Med       Date:  2014-02-18       Impact factor: 2.447

5.  Transthyretin increases migration and invasion of rat placental trophoblast cells.

Authors:  Xiao-Peng Ma; Chong-Dong Liu; Guang-Ming Cao; Zhen-Yu Zhang
Journal:  FEBS Open Bio       Date:  2020-07-01       Impact factor: 2.693

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.